Gvia^®-ET

Therapeutic Segment:
Anti-diabetic

Generic Name:
Ertugliflozin+Sitagliptin

Description:
Gvia-ET (Ertugliflozin + Sitagliptin) tablet for oral use contains ertugliflozin L-pyroglutamic acid,a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor.

Indication:
Gvia-ET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.

Formulation:

• Tablets

Strength:

• 5mg+100mg
• 15mg/100mg

Pack Size:

• 14’s
• 28’s